N
BCYC

Natixis’s Bicycle Therapeutics BCYC Stock Holding History

Natixis’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.2K Hold
4,645
– – ﹤0.01% 1007
2025
Q4 		$31.6K Buy
4,645
+2,698
+139% +$19.9K ﹤0.01% 1020
2025
Q3 		$14.6K Hold
1,947
– – ﹤0.01% 979
2025
Q2 		$13.9K Sell
1,947
-179
-8% -$1.43K ﹤0.01% 945
2025
Q1 		$17.9K Sell
2,126
-172
-7% -$2.03K ﹤0.01% 876
2024
Q4 		$33.2K Sell
2,298
-437
-16% -$9.37K ﹤0.01% 913
2024
Q3 		$62.8K Sell
2,735
-147
-5% -$3.39K ﹤0.01% 775
2024
Q2 		$57.9K Buy
2,882
+314
+12% +$7.09K ﹤0.01% 778
2024
Q1 		$63.2K Sell
2,568
-61
-2% -$1.3K ﹤0.01% 811
2023
Q4 		$47.6K Sell
2,629
-139
-5% -$2.3K ﹤0.01% 829
2023
Q3 		$55.1K Sell
2,768
-7
-0.3% -$160 ﹤0.01% 816
2023
Q2 		$69.9K Sell
2,775
-625
-18% -$14.5K ﹤0.01% 822
2023
Q1 		$73.7K Sell
3,400
-213
-6% -$5.34K ﹤0.01% 806
2022
Q4 		$107K Buy
+3,613
New +$96.9K ﹤0.01% 870

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis's BCYC Position: Q1 2026 in Review

Natixis held its Bicycle Therapeutics (BCYC) position steady in Q1 2026 at 4,645 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Natixis first reported a position in BCYC in Q4 2022 and has held it in 14 quarters since. The position peaked at $107K in Q4 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Natixis held 4,645 shares of Bicycle Therapeutics worth $21.2K as of Q1 2026.
  • Natixis left its Bicycle Therapeutics share count unchanged in Q1 2026.
  • Bicycle Therapeutics made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1007 holding.
  • Natixis first reported a position in Bicycle Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Natixis's Bicycle Therapeutics position peaked at $107K in Q4 2022.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.